SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Economy
Sanders Rips Pharma Giant for Charging $900+ for Drug That Could Be Sold for $100
"Why? Excessive corporate greed," said Sen. Bernie Sanders.
Sep 17, 2024
U.S. Sen. Bernie Sanders called out the pharmaceutical giant Novo Nordisk on Tuesday for charging American patients more than $900 a month for the increasingly popular diabetes drug Ozempic, even though generic manufacturers are willing to sell the medication for significantly less.
During a panel discussion with experts, Sanders (I-Vt.) said he and his staff have been in contact with the top executives of major drug makers who say they could sell a generic version of Ozempic for less than $100 a month—and still turn a profit. A recent study found that the drug can be manufactured for less than $5 a month.
"Novo Nordisk, which has made nearly $50 billion in sales off of Ozempic and Wegovy, charges Americans almost $1,000 a month—the highest prices in the world," Sanders, the chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, said Tuesday. "Why? Excessive corporate greed."
Ozempic and Wegovy are part of a class of treatments known as GLP-1s. Wegovy, a weight-loss drug that Novo Nordisk sells for $1,349 a month in the U.S., contains the same active ingredient as Ozempic, which is approved only for people with Type 2 diabetes.
The drugs' growing popularity in the U.S. has drawn greater scrutiny to Novo Nordisk's pricing. Sanders' office noted Tuesday that the company's price tag for Wegovy is $186 in Denmark, $140 in Germany, and $92 in the United Kingdom.
Novo Nordisk's high prices for the drugs in the U.S. could have far-reaching impacts on the nation's healthcare system. A group of economists wrote in a recent op-ed for The New York Times earlier this year that "under reasonable assumptions and at current prices, making this class of drugs available to all obese Americans could eventually cost over $1 trillion per year," which is "almost as much as the government spends on the entireMedicare program and almost one-fifth of the entire amount America spends on healthcare."
Sanders warned Tuesday that if the prices of Ozempic and Wegovy aren't reined in, Medicare premiums could surge.
"Our healthcare system, I think most people understand, is in crisis," Sanders said during the panel discussion. "The business model of the pharmaceutical industry is unsustainable."
Over the course of our investigation into the outrageous cost of Ozempic and Wegovy in the U.S., I spoke with the CEOs of major generic pharmaceutical companies who confirmed:
They can sell a generic version of Ozempic for $100/mo. https://t.co/XDHdBRPIcM
— Bernie Sanders (@SenSanders) September 17, 2024
Peter Maybarduk, director of the Access to Medicines Program at Public Citizen, said in a statement Tuesday that "all we need to make Ozempic for $100 a reality is to overcome Novo's patent monopoly, which the government has the power to do any time."
"States and clinicians are asking the feds for help," said Maybarduk. "We estimate taking action on Novo's patents could save Medicare more than $14 billion in the first two years of competition, while making diabetes and obesity drugs affordable."
Last month, Public Citizen delivered a petition to U.S. Health and Human Services Secretary Xavier Becerra urging him to use existing law to "authorize generic competitors to Ozempic and Wegovy."
"Novo Nordisk’s outrageous pricing of [Ozempic and Wegovy] threatens to break the coffers of federal health programs," the group wrote. "Pursuant to 28 U.S.C. § 1498, the administration should authorize use of any and all patents necessary to allow manufacturers to produce generic alternatives to these treatments on behalf of the United States government, which can be used to supply Medicare, Medicaid, and other federal health programs. This will facilitate competition and make the treatments more affordable and accessible for patients."
The CEO of Novo Nordisk, which has spent aggressively on lobbying this year, is scheduled to testify before the Senate HELP Committee next week.
Keep ReadingShow Less
Ahead of Senate Hearing, Doctors Decry 'Exorbitant' Cost of Ozempic and Wegovy
"Too often, because manufacturers are pricing out my patients, I have to resort to treatment options that are less effective and less safe," one doctor said.
Sep 16, 2024
As the U.S. Senate prepares for a hearing on Novo Nordisk overcharging Americans for Ozempic and Wegovy, Sen. Bernie Sanders on Monday released a letter from 253 health professionals asking Congress to take on the "exorbitant prices set by manufacturers" for non-insulin diabetes and weight loss medications.
The clinicians wrote that drugs including "semaglutide (marketed by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss) and... tirzapetide (marketed by Eli Lilly as Mounjaro for diabetes and Zepbound for weight loss) have been revolutionary in the management of chronic conditions of diabetes and obesity."
"However, even the most transformative medications cannot help our patients if they cannot afford them," states the letter, which is addressed to Sanders (I-Vt.), chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP), and Sen. Bill Cassidy (R-La.), the panel's ranking member.
"If Novo Nordisk does not end its greed and substantially reduce the price of these drugs, we must do everything we can to end it for them."
"Studies have shown that semaglutide can be manufactured for as little as nearly $5 per month, substantially lower than the current U.S. list price of $968 for Ozempic or $1,349 per month for Wegovy," the letter notes. "In contrast, Novo Nordisk has set the price of Wegovy at $92 in the United Kingdom and $186 in Denmark, clearly demonstrating that these drugs are being priced unfairly for our U.S. patients."
The health providers stressed that "for patients, these are not one-off prices they shoulder, but potentially lifelong costs they will need to consider. For obesity, the drugs work while patients take them, but once off treatment, studies have found that patients regain the weight."
"Patients in the U.S. face multiple hurdles in accessing the drugs, which we as prescribers do our best to help them navigate," they explained, detailing issues faced by people who have private insurance, Medicare and Medicaid coverage, and no insurance. "Lack of coverage, supply shortages, and the unreasonable sticker prices of these medications are pushing patients to consider alternative options, which are often unsafe."
"We want our patients to be able to access medications that can improve their health and quality of life, but we do not want to rob the American taxpayers to line the pockets of the pharmaceutical manufacturers," the clinicians concluded. "Senators, we are asking you to do everything in your power to bring down the price of these novel diabetes and obesity drugs. Our patients deserve to have the best options available to them at a fair price."
Echoing the letter in a Monday statement, Dr. Kasia Lipska, a practicing endocrinologist and diabetes researcher at the Yale School of Medicine in Connecticut, said that "the exorbitant prices that manufacturers are asking my patients to pay for these novel diabetes and obesity medications are simply unacceptable."
"Too often, because manufacturers are pricing out my patients, I have to resort to treatment options that are less effective and less safe," Lipska continued. "These are life-changing treatments that should be available to my patients and everyone who needs them, not just those who can afford to pay."
Dr. Elizabeth Dewey, another letter signatory who practices family medicine in Greensboro, North Carolina, said that in her state, "we have been struggling all year with lack of coverage for weight loss medications."
"When our state plan and large employers dropped coverage for weight loss medications earlier this year, patients were left without treatment," Dewey explained. "Those who wanted to continue on the medications could pay cash. But for most patients, paying hundreds of dollars without insurance coverage is not affordable. Even with drug company coupons or discounts on certain doses, these treatments are still unattainable for most of my patients."
Sanders, who launched a probe into Denmark-based Novo Nordisk back in April, welcomed the letter, saying that "doctors across this country are sick and tired of seeing their patients ripped off by giant pharmaceutical companies."
"There is no rational reason, other than greed, for Novo Nordisk to charge Americans with Type 2 diabetes $969 a month for Ozempic, while this same exact drug can be purchased for just $155 in Canada and just $59 in Germany," he argued. "Novo Nordisk also charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $140 in Germany."
"Doctors agree," he added. "If Novo Nordisk does not end its greed and substantially reduce the price of these drugs, we must do everything we can to end it for them."
The Senate HELP Committee hearing on Capitol Hill is scheduled for 10:00 am on Tuesday, September 24.
Keep ReadingShow Less
Thousands of Autoworkers Protest in Brussels Amid Likely Audi Layoffs
"Their anger is very legitimate, very understandable, especially since Audi is not very clear on its plans," a local employment minister said.
Sep 16, 2024
Thousands of autoworkers protested in Brussels on Monday following recent news that Audi, a subsidiary of the German automaker Volkswagen, would phase out production at its plant there, which is expected to mean layoffs for its roughly 3,000 employees by the end of 2025.
The phase-out announcement led to a labor dispute that's shuttered the plant for the last two weeks, with some employees forming an encampment protest outside. The plant is expected to resume operations on Tuesday even though the core issues underlying the labor dispute, which some unions have characterized as a lockout by management, haven't been resolved.
Between 5,500 and 11,000 demonstrators marched toward the European Parliament on Monday, bringing "chaos" to Brussels, where public transport was largely shut down. Unions not directly affected by the Audi plant's likely closure participated in solidarity.
"Their anger is very legitimate, very understandable, especially since Audi is not very clear on its plans," Bernard Clerfayt, a local employment minister, toldAFP.
Charlie Le Paige of Belgium's worker's party, Parti du Travail de Belgique, wrote on social media that there were "lots and lots of people in the streets of Brussels in support of Audi workers and subcontractors."
Le Paige said that the company was treating employees as disposable while distributing huge amounts of money to shareholders, and declared that "workers are not adjustment variables!"
Beaucoup beaucoup de monde dans les rues de Bruxelles en soutien aux travailleurs et aux sous-traitants d'#Audi 🔥 Le groupe VW-Audi a distribué près de 12 milliards de dividendes l'année passée, les travailleurs ne sont pas des variables ajustement! pic.twitter.com/aUEgbCNZsl
— Charlie Le Paige (@charlielepaige) September 16, 2024
The state-of-the-art Audi plant in southern Brussels produces the Q8 e-Tron, an electric sport utility vehicle. Audi received about 27 million euros ($30 million) in public funding to retrain workers when it converted to electric vehicle production.
Audi announced in July that it was considering discontinuing production of the commercially unsuccessful Q8 e-Tron and closing the Brussels plant, and said earlier this month that it still hadn't found an alternative vehicle that it could produce there.
The following day, September 4, the plant's workers "downed tools" and set up protest camps on the premises, according toWorld Socialist Web Site.
On September 6, United Auto Workers President Shawn Fain, a leading U.S. unionist, visited the plant in solidarity with the workers there.
About 1,500 Audi workers at the plant face the prospect of layoffs as early as next month, another 1,100 by May, and the remainder by the end of 2025. There are also many hundreds of subcontractor workers that would be impacted by a closure, unions have said.
Last week, workers took about 200 car keys from vehicles at the plant as an act of protest, prompting warnings of legal action by the company. The workers later returned the keys to try to facilitate discussions with management.
The plant's likely closure is seen as part of E.V. failures at Volkswagen and European carmakers more generally, prompting calls for the European Union to invest in and protect the industry. Audi reportedly plans to make the successor to the Q8 e-Tron in Mexico.
Many of the demonstrators on Monday spoke harshly about E.U. policy.
"We also want to send a strong signal to European authorities, which are making things difficult for Belgian industry, but also for European industry," Patrick Van Belle, a leading union official at Audi Brussels, toldReuters, in explaining the reasons for Monday's demonstration. "The manufacturing industry is mainly migrating away from our countries."
Volkswagen's layoffs may in fact extend beyond Belgium. The company made the surprising announcement earlier this month that it may shutter factories in Germany, drawing fierce opposition from unions there. The closures would be the first in Germany in the company's 87-year history.
Former European Central Bank chief Mario Draghi last week issued a report, commissioned by the E.U., calling for stronger industrial policy and a degree of trade protectionism, including in the auto industry, which is struggling to compete with heavily subsidized Chinese vehicles. Draghi, hardly considered a radical political thinker, drew criticism from neoliberal institutions for the proposals.
Local police said about 5,500 people attended the demonstration on Monday while unions put the figure at 11,000.
Keep ReadingShow Less
After Historic Union Vote, Chattanooga VW Workers Rally for 'Record Contract'
"You're the backbone of this plant, you're the backbone of this company, and you deserve your fair share of the wealth that you create," UAW President Shawn Fain told workers.
Sep 15, 2024
Following their historic vote to join the United Auto Workers in April, workers at a Volkswagen plant in Chattanooga, Tennessee held a rally on Sunday as they prepare to head into their first round of negotiations with the company next week.
With their vote, the Chattanooga workers became the first Southern automakers not affiliated with one of the Big Three auto companies to win a union.
"Just a few months ago, you voted 3-1 to join the UAW," the union's president Shawn Fain told the assembled workers, adding, "You had faith, and you moved mountains, you overcame opposition, and you won your union."
"With the kinds of profits you're generating, Volkswagen could double your wages, not raise prices, and still make billions of dollars. It's a choice."
At a rally that began at 1:30 pm Eastern Time on Sunday, Fain told gathered workers that they were now ready for the "next step."
"We tell Volkswagen, get out your pens, because it's time to put it down in writing," Fain said.
Heading into negotiations, the UAW is set to make several demands of Volkswagen, among them improved health and safety; competitive wages including cost of living allowances, profit sharing, and no tiers; improved paid-time-off polices; more retirement security; affordable healthcare; and union protections such as due process, union representation, paid time for union work, job training, and fair promotion policies.
Fain warned the workers that the company and the corporate media would try to fearmonger about the union's demands.
"They're going to say that our righteous fight for a high quality of life for the working class will wreck the economy or derail the transition to EV," Fain said, adding, "The only economy that's going to get wrecked in this is their economy that only works for the rich and the corporate class."
Fain shared figures showing that Volkswagen had increased its profits since 2021 by 49% compared with the previous three years, securing $24 billion in profits in 2023 alone. But instead of sharing that windfall equitably with the workforce and the local economy, it paid CEO Oliver Blume $10.5 million and wealthy shareholders $12.7 billion. Shareholders have seen their dividends jump by 288% in two years.
"That's billions of dollars that have been robbed from the workers who generated those profits," Fain said. "It's billions of dollars that weren't spent on the EV transition. It's billions of dollars being spent on mansions in faraway countries and yachts in private marinas, and not being spent in the local businesses right here in Tennessee."
At the same time, workers at the Chattanooga plant had produced more than 1.5 million vehicles for over $50 billion in sales since 2011.
"You're the backbone of this plant, you're the backbone of this company, and you deserve your fair share of the wealth that you create," Fain said, adding, "With the kinds of profits you're generating, Volkswagen could double your wages, not raise prices, and still make billions of dollars. It's a choice."
Ultimately, Fain said the figures he cited had one cause: "corporate greed."
Fain noted that the Chattanooga workers were entering negotiations for their first union contract roughly one year after UAW workers at the Big Three car makers launched their historic "stand up strike, ultimately winning record-breaking contracts from General Motors, Ford, and Stellantis.
"Since that moment, workers everywhere including here at Volkswagen are standing up to fight corporate greed and demand your fair share in the economy," Fain said.
He told the Chattanooga workers, "Now is your time to win a record contract and make history again."
Keep ReadingShow Less
Most Popular